Abstract
Bis(allixinato)oxovanadium(IV), VO(alx)2 (alx is 3-hydroxy-5-methoxy-6-methyl-2-pentyl-4-pyrone), has been reported to act as an antidiabetic agent in streptozotocin-induced type-1-like and obesity-linked KKAy type 2 diabetic model mice. VO(alx)2 is also proposed as a candidate agent for treating metabolic syndromes in animals. However, its functional mechanism is yet to be clarified. In this study, we examined whether VO(alx)2 contributes to both the activation of the insulin signaling cascade that activates glucose transporter 4 (GLUT4) translocation and the regulation of the forkhead box O1 (FoxO1) transcription factor that controls the gene transcription of gluconeogenesis genes. The following three important results were obtained: (1) intracellular vanadium concentration in 3T3-L1 adipocytes is higher after treatment with VO(alx)2 than with VOSO4; (2) VO(alx)2 stimulates the translocation of GLUT4 to the plasma membrane following activation of the tyrosine phosphorylation of the insulin receptor β-subunit (IRβ) and insulin receptor substrate (IRS) as well as Akt kinase in 3T3-L1 adipocytes; and (3) the mechanism of inhibition of glucose-6-phosphatase (G6Pase) catalytic subunit gene expression by vanadium is due to disruption of FoxO1 binding with the G6Pase promoter, which indicates that FoxO1 is phosphorylated by VO(alx)2-stimulated Akt in HepG2 cells. On the basis of these results, we propose that the critical functions of VO(alx)2 involve the activation of phosphatidylinositol 3-kinase–Akt signaling through the enhancement of tyrosine phosphorylation of IRβ and IRS, which in turn transmits the signal to activate GLUT4 translocation, and the regulation of the DNA binding activity of the FoxO1 transcription factor.
Similar content being viewed by others
Abbreviations
- BSA:
-
Bovine serum albumin
- ChIP:
-
Chromatin immunoprecipitation
- DM:
-
Diabetes mellitus
- DMEM:
-
Dulbecco’s modified Eagle’s medium
- DTT:
-
Dithiothreitol
- EGTA:
-
Ethylene glycol bis(2-aminoethyl ether)tetraacetic acid
- FBS:
-
Fetal bovine serum
- FITC:
-
Fluorescein isothiocyanate
- FoxO1:
-
Forkhead box O1
- G6Pase:
-
Glucose-6-phosphatase
- GLUT4:
-
Glucose transporter 4
- GSK3β:
-
Glycogen synthase kinase-3β
- Hepes:
-
N-(2-Hydroxyethyl)piperazine-N′-ethanesulfonic acid
- HNMPA-(AM)3 :
-
Hydroxy-2-naphthalenylmethylphosphonic acid tris(acetoxymethyl) ester
- IRβ:
-
Insulin receptor β-subunit
- IRE:
-
Insulin regulatory element
- IRS:
-
Insulin receptor substrate
- MAPK:
-
Mitogen-activated protein kinase
- PBS:
-
Phosphate-buffered saline
- PBST:
-
Phosphate-buffered saline containing 0.1% Tween 20
- PEPCK:
-
Phosphoenolpyruvate carboxykinase
- PI3K:
-
Phosphatidylinositol 3-kinase
- PKA:
-
Protein kinase A
- PMSF:
-
Polymethylsulfonyl fluoride
- pNP:
-
p-Nitrophenol
- pNPP:
-
p-Phosphonitrophenol
- SDS:
-
Sodium dodecyl sulfate
- STZ:
-
Streptozotocin
- TBS:
-
Tris(hydroxymethyl)aminomethane (Tris)-buffered saline
- Tris:
-
Tris(hydroxymethyl)aminomethane
- VO(alx)2 :
-
Bis(allixinato)oxovanadium(IV)
- VO(ma)2 :
-
Bis(maltolato)oxovanadium(IV)
References
Wild S, Roglic G, Green A, Sicree R, King H (2004) Diabetes Care 27:1047–1053
Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T (2002) Diabetes Res Clin Pract 55:65–85
Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A (2006) Ann N Y Acad Sci 1084:89–117
Muoio DM, Newgard CB (2006) Annu Rev Biochem 75:367–401
Herman MA, Kahn BB (2006) J Clin Invest 116:1767–1775
Rosen ED, Spiegelman BM (2006) Nature 444:847–853
Saltiel AR, Pessin JE (2002) Trends Cell Biol 12:65–71
Watson RT, Pessin JE (2006) Trends Biochem Sci 31:215–222
Shepherd PR, Kahn BB (1999) N Engl J Med 341:248–257
Postic C, Dentin R, Girard J (2004) Diabetes Metab 30:398–408
Moller DE (2001) Nature 414:821–827
Stumvoll M (2003) Expert Opin Investig Drugs 12:1179–1187
Olefsky JM (2000) J Clin Invest 106:467–472
Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Science 293:1673–1677
Zhang ZY, Lee SY (2003) Expert Opin Investig Drugs 12:223–233
Crans DC, Smee JJ, Gaidamauskas E, Yang L (2004) Chem Rev 104:849–902
Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR (1995) Mol Cell Biochem 153:217–231
Sakurai H, Katoh A, Yoshikawa Y (2006) Bull Chem Soc Jpn 79:1645–1664
Thompson KH, Orvig C (2006) J Inorg Biochem 100:1925–1935
Fantus IG, Kadota S, Deragon G, Foster B, Posner BI (1989) Biochemistry 28:8864–8871
Nakai M, Watanabe H, Fujiwara C, Kakegawa H, Satoh T, Takada J, Matsushita R, Sakurai H (1995) Biol Pharm Bull 18:719–725
Sekar N, Li J, He Z, Gefel D, Shechter Y (1999) Endocrinology 140:1125–1131
Mohammad A, Sharma V, McNeill JH (2002) Mol Cell Biochem 233:139–143
Marzban L, Rahimian R, Brownsey RW, McNeill JH (2002) Endocrinology 143:4636–4645
Srivastava AK, Mehdi MZ (2005) Diabet Med 22:2–13
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Nature 378:785–789
O’Connor JC, Freund GG (2003) Metabolism 52:666–674
Papapetropoulos A, Fulton D, Lin MI, Fontana J, McCabe TJ, Zoellner S, Garcia-Cardena G, Zhou Z, Gratton JP, Sessa WC (2004) Mol Pharmacol 65:407–415
Jelveh KA, Zhande R, Brownsey RW (2006) J Biol Inorg Chem 11:379–388
Lu B, Ennis D, Lai R, Bogdanovic E, Nikolov R, Salamon L, Fantus C, Le-Tien H, Fantus IG (2001) J Biol Chem 276:35589–35598
Nechay BR (1984) Annu Rev Pharmacol Toxicol 24:501–524
Kawabe K, Yoshikawa Y, Adachi Y, Sakurai H (2006) Life Sci 78:2860–2866
Adachi Y, Yoshida J, Kodera Y, Katoh A, Takada J, Sakurai H (2006) J Med Chem 49:3251–3256
Adachi Y, Yoshikawa Y, Yoshida J, Kodera Y, Katoh A, Takada J, Sakurai H (2006) Biochem Biophys Res Commun 345:945–950
Basuki W, Hiromura M, Adachi Y, Tayama K, Hattori M, Sakurai H (2006) Biochem Biophys Res Commun 349:1163–1170
Ishiki M, Randhawa VK, Poon V, Jebailey L, Klip A (2005) J Biol Chem 280:28792–28802
Laemmli UK (1970) Nature 227:680–685
Hill MM, Hemmings BA (2002) Methods Enzymol 345:448–463
Hiromura M, Okada F, Obata T, Auguin D, Shibata T, Roumestand C, Noguchi M (2004) J Biol Chem 279:53407–53418
Hiromura M, Suizu F, Narita M, Kinowaki K, Noguchi M (2006) J Biol Chem 281:27753–27764
Usheva A, Shenk T (1996) Proc Natl Acad Sci USA 93:13571–13576
Kang SH, Vieira K, Bungert J (2002) Nucleic Acids Res 30:e44
Weinmann AS, Farnham PJ (2002) Methods 26:37–47
Mehdi MZ, Srivastava AK (2005) Arch Biochem Biophys 440:158–164
Mehdi MZ, Vardatsikos G, Pandey SK, Srivastava AK (2006) Biochemistry 45:11605–11615
Perry MC, Hales CN (1969) Biochem J 115:865–871
Girolamo MD, Mendlinger S (1971) Am J Physiol 221:859–863
Castan I, Wijkander J, Manganiello V, Degerman E (1999) Biochem J 339:281–289
Pandey SK, Anand-Srivastava MB, Srivastava AK (1998) Biochemistry 37:7006–7014
Baltensperger K, Lewis RE, Woon CW, Vissavajjhala P, Ross AH, Czech MP (1992) Proc Natl Acad Sci USA 89:7885–7889
Saperstein R, Vicario PP, Strout HV, Brady E, Slater EE, Greenlee WJ, Ondeyka DL, Patchett AA, Hangauer DG (1989) Biochemistry 28:5694–5701
O’Brien RM, Streeper RS, Ayala JE, Stadelmaier BT, Hornbuckle LA (2001) Biochem Soc Trans 29:552–558
Nakae J, Kitamura T, Silver DL, Accili D (2001) J Clin Invest 108:1359–1367
Matsumoto M, Han S, Kitamura T, Accili D (2006) J Clin Invest 116:2464–2472
Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, Klotsas A, Matika R, Xiao X, Franks R, Heidenreich KA, Sajan MP, Farese RV, Stolz DB, Tso P, Koo SH, Montminy M, Unterman TG (2006) J Biol Chem 281:10105–10117
Nakae J, Kitamura T, Kitamura Y, Biggs WH III, Arden KC, Accili D (2003) Dev Cell 4:119–129
Tang ED, Nunez G, Barr FG, Guan KL (1999) J Biol Chem 274:16741–16746
Rena G, Guo S, Cichy SC, Unterman TG, Cohen P (1999) J Biol Chem 274:17179–17183
Vander Kooi BT, Streeper RS, Svitek CA, Oeser JK, Powell DR, O’Brien RM (2003) J Biol Chem 278:11782–11793
White MF, Kahn CR (1994) J Biol Chem 269:1–4
Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D (2000) Mol Cell 6:1401–1412
Zabolotny JM, Haj FG, Kim YB, Kim HJ, Shulman GI, Kim JK, Neel BG, Kahn BB (2004) J Biol Chem 279:24844–24851
Pannifer AD, Flint AJ, Tonks NK, Barford D (1998) J Biol Chem 273:10454–10462
Fukui K, Fujisawa Y, Oha-Nishiguchi H, Kamada H, Sakurai H (1999) J Inorg Chem 77:215–224
Bosch F, Hatzoglou M, Park EA, Hanson RW (1990) J Biol Chem 265:13677–13682
Valera A, Rodriguez-Gil JE, Bosch F (1993) J Clin Invest 92:4–11
Plas DR, Thompson CB (2005) Oncogene 24:7435–7442
Taniguchi CM, Emanuelli B, Kahn CR (2006) Nat Rev Mol Cell Biol 7:85–96
Acknowledgement
This study was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government [Grants-in-Aid for Scientific Research (B), Scientific Research on Priority Areas, and Specially Promoted Research] to H.S.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hiromura, M., Nakayama, A., Adachi, Y. et al. Action mechanism of bis(allixinato)oxovanadium(IV) as a novel potent insulin-mimetic complex: regulation of GLUT4 translocation and FoxO1 transcription factor. J Biol Inorg Chem 12, 1275–1287 (2007). https://doi.org/10.1007/s00775-007-0295-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-007-0295-x